The scoop: The money is being used to engineer late-stage work on Mydicar, a heart failure treatment that recently gained fast-track status at the FDA. It also marks a major milestone for Celladon, which announced 5 years ago that it had raised $30 million from Kleiner Perkins and others to get Mydicar into the clinic.

Editor's note: This story has been updated with new information from Thomson Reuters.